RxDoctor Payments Data

William Clare, MD

Internal Medicine · Chas, SCNPI 1861449662

Payments from drug & device makers

$316in general payments, 2019–2025

Across 18 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$66
  • Abbott$50
  • Otsuka America Pharmaceutical, Inc.$27
  • Ultragenyx Pharmaceutical Inc.$25
  • Bayer$21
  • Idorsia Pharmaceuticals US Inc$19
  • plus $108 from 7 others

What the payments were for

  • Food & beverage$316100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$316 in reported general payments places this provider in the 50th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$146,961
Medicare patients
475
Services billed
2,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide136$145,184
EliquisApixaban73$83,069
JardianceEmpagliflozin86$74,027
JanuviaSitagliptin Phosphate51$50,985
FarxigaDapagliflozin Propanediol32$37,301
MounjaroTirzepatide19$28,367
XareltoRivaroxaban14$19,281
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,303
PlaquenilHydroxychloroquine Sulfate12$10,671
Praluent PenAlirocumab13$6,153
Atorvastatin Calcium514$5,311
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$4,297
Losartan Potassium374$4,030
Memantine Hcl36$3,822
Rosuvastatin Calcium225$3,546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$13$145,184136 claims
Boehringer IngelheimJardiance$15$74,02786 claims
AstraZenecaFarxiga, Symbicort$16$40,19744 claims
Lilly USA, LLCMounjaro$66$28,36719 claims
GSKTrelegy Ellipta$12$15,30320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Chas

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →